News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • ADB president warned the yen may weaken further if the BOJ delays tightening, increasing FX volatility in Asia.
  • He urged targeted policy measures instead of broad subsidies to curb yen selling.
  • ICE reported 17 detainee deaths from January through early April 2026, after 31 deaths in 2025.
  • Families and local officials disputed ICE's summaries and some deaths remain under investigation.
  • Analysts say QuidelOrtho could re-rate if management delivers the projected 2026 free-cash-flow turnaround.
  • Pliant Therapeutics reported large tumor responses to PLN-101095 plus pembrolizumab in ICI-refractory tumors and will expand Phase 1b.

Latest Articles

Skeena Gold & Silver Confirms Eskay Creek Reaches 49% Completion & Provides Project Update; Initial Production Remains on Schedule for Q2 2027

Skeena Gold & Silver Confirms Eskay Creek Reaches 49% Completion & Provides Project Update; Initial Production Remains on Schedule for Q2 2027

Skeena Gold & Silver reports achieving 49% completion of its Eskay Creek Gold-Silver Project with initial production expected in Q2 2027. The project's updated construction budget stands at US$659 million, up from the 2023 estimate of US$560 million, due to inflation, enhanced environmental and permitting requirements, and design updates. The compa…

Birchtech Reports Fourth Quarter 2025 Financial Results

Birchtech Reports Fourth Quarter 2025 Financial Results

Birchtech Corp. announced its fourth quarter and full year 2025 financial results, highlighting a 19.8% year-over-year increase in product revenues and a $0.8 million improvement in net loss. The company successfully uplisted to the NYSE American in February 2026, raising $16.6 million to enhance its financial position. Additionally, Birchtech secu…

MAAS Completes Strategic Acquisition of Huazhi Future, Establishing Full-Stack AI Self-Controllability

MAAS Completes Strategic Acquisition of Huazhi Future, Establishing Full-Stack AI Self-Controllability

Maase Inc. (NASDAQ: MAAS) finalized its acquisition of Huazhi Future, marking a strategic transition from a scenario operator to an AI industry player with integrated full-stack AI capabilities. The acquisition enables MAAS to combine computing infrastructure, proprietary AI algorithms, intelligent hardware, and operational services into a comprehe…

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences has begun screening the first patient in its global Phase 3 confirmatory trial of roluperidone, a drug candidate designed to treat negative symptoms of schizophrenia such as avolition, anhedonia, and social withdrawal—symptoms for which there are currently no FDA-approved therapies. The trial plans to enroll approximately 380 …

Tenaris Files its 2025 Annual Report and its Annual Report on Form 20-F

Tenaris Files its 2025 Annual Report and its Annual Report on Form 20-F

Tenaris S.A., a leading global supplier of steel tubes for the energy sector and other industries, filed its 2025 Annual Report with the Luxembourg Stock Exchange and other regulators, including the U.S. SEC. The report includes consolidated financial statements, sustainability information, and auditor certifications. The Form 20-F will be filed wi…

SPAR Group, Inc. Issues Fiscal Year 2026 Financial Guidance

SPAR Group, Inc. Issues Fiscal Year 2026 Financial Guidance

SPAR Group, Inc. announced its financial guidance for fiscal year 2026, projecting net sales between $143 million and $151 million, and gross margins improving to 20.5%-22.5%. The company highlighted a favorable shift towards higher-margin core merchandising services, cost reductions, ongoing AI implementation for efficiency, and recent capital rai…

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Oculis Holding AG announced that the European Medicines Agency granted Priority Medicines (PRIME) designation to its neuroprotective candidate Privosegtor for optic neuritis (ON), following a prior FDA Breakthrough Therapy designation. Supported by positive Phase 2 trial results demonstrating significant improvements in visual function and neuropro…

Workhorse Group Reports Fourth Quarter and Full Year 2025 Results

Workhorse Group Reports Fourth Quarter and Full Year 2025 Results

Workhorse Group Inc. announced its fourth quarter and full year 2025 financial results, marking its first earnings report after merging with Motiv Electric Trucks. The company reported a 64% revenue increase in Q4 and a 201% rise for the full year, driven by vehicle deliveries and product lineup expansion. Workhorse is targeting $20 million in annu…

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORIC Pharmaceuticals announced the selection of 400 mg once daily rinzimetostat (ORIC-944) in combination with darolutamide as the recommended Phase 3 dose (RP3D) for the Himalayas-1 global Phase 3 registrational trial in post-abiraterone metastatic castration-resistant prostate cancer (mCRPC). Phase 1b data show favorable safety and promising effi…

TOMI Environmental Solutions, Inc. Reports Full Year 2025 Financial Results and Outlines Growth Initiatives

TOMI Environmental Solutions, Inc. Reports Full Year 2025 Financial Results and Outlines Growth Initiatives

TOMI Environmental Solutions, Inc. announced its financial results for the year ended December 31, 2025. Despite a 27% decline in net sales due primarily to deferred capital expenditures amid economic uncertainty, the company improved its operating loss compared to 2024. TOMI continued to expand its global market presence, secured notable governmen…

Barfresh Announces Fourth Quarter and Full Year 2025 Results

Barfresh Announces Fourth Quarter and Full Year 2025 Results

Barfresh Food Group Inc. announced record revenue for 2025 of $14.2 million, driven by the acquisition of Arps Dairy and expanded school penetration. The company provided optimistic 2026 guidance with expected revenue between $28 million and $32 million, reflecting nearly 100% growth year-over-year. Barfresh secured $7.5 million in convertible note…

Rigetti Announces Novera QPU Sale to the University of Saskatchewan

Rigetti Announces Novera QPU Sale to the University of Saskatchewan

Rigetti Computing announced the sale and shipment of its 9-qubit Novera quantum processing unit (QPU) to the University of Saskatchewan, marking the establishment of USask's first quantum computing system. The system will be managed by the university's Centre for Quantum Topology and its Applications and aims to support innovative research in quant…

nCino Reports Fourth Quarter and Fiscal Year 2026 Financial Results

nCino Reports Fourth Quarter and Fiscal Year 2026 Financial Results

nCino, Inc., a leading provider of intelligent banking solutions, reported strong financial results for the fourth quarter and fiscal year 2026, exceeding all financial guidance metrics. The company achieved record annual contract value (ACV) of $602.4 million, up 17% year-over-year, and a fiscal 2026 ACV net retention rate of 112%. Total revenues …